269 related articles for article (PubMed ID: 12002517)
21. Novel hexahydrospiro[piperidine-4,1'-pyrrolo[3,4-c]pyrroles]: highly selective small-molecule nociceptin/orphanin FQ receptor agonists.
Kolczewski S; Adam G; Cesura AM; Jenck F; Hennig M; Oberhauser T; Poli SM; Rössler F; Röver S; Wichmann J; Dautzenberg FM
J Med Chem; 2003 Jan; 46(2):255-64. PubMed ID: 12519064
[TBL] [Abstract][Full Text] [Related]
22. [(pF)Phe4,Arg14,Lys15]N/OFQ-NH2 (UFP-102), a highly potent and selective agonist of the nociceptin/orphanin FQ receptor.
Carrà G; Rizzi A; Guerrini R; Barnes TA; McDonald J; Hebbes CP; Mela F; Kenigs VA; Marzola G; Rizzi D; Gavioli E; Zucchini S; Regoli D; Morari M; Salvadori S; Rowbotham DJ; Lambert DG; Kapusta DR; Calo' G
J Pharmacol Exp Ther; 2005 Mar; 312(3):1114-23. PubMed ID: 15509719
[TBL] [Abstract][Full Text] [Related]
23. [Nphe(1)]NC(1-13)NH(2) selectively antagonizes nociceptin/orphanin FQ-stimulated G-protein activation in rat brain.
Berger H; Calo' G; Albrecht E; Guerrini R; Bienert M
J Pharmacol Exp Ther; 2000 Aug; 294(2):428-33. PubMed ID: 10900215
[TBL] [Abstract][Full Text] [Related]
24. N- and C-terminal modifications of nociceptin/orphanin FQ generate highly potent NOP receptor ligands.
Guerrini R; Caló G; Lambert DG; Carrá G; Arduin M; Barnes TA; McDonald J; Rizzi D; Trapella C; Marzola E; Rowbotham DJ; Regoli D; Salvadori S
J Med Chem; 2005 Mar; 48(5):1421-7. PubMed ID: 15743186
[TBL] [Abstract][Full Text] [Related]
25. Effects of receptor density on Nociceptin/OrphaninFQ peptide receptor desensitisation: studies using the ecdysone inducible expression system.
Barnes TA; McDonald J; Rowbotham DJ; Duarte TL; Lambert DG
Naunyn Schmiedebergs Arch Pharmacol; 2007 Nov; 376(3):217-25. PubMed ID: 17899014
[TBL] [Abstract][Full Text] [Related]
26. Antitussive profile of the NOP agonist Ro-64-6198 in the guinea pig.
McLeod RL; Jia Y; Fernandez X; Parra LE; Wang X; Tulshian DB; Kiselgof EJ; Tan Z; Fawzi AB; Smith-Torhan A; Zhang H; Hey JA
Pharmacology; 2004 Jul; 71(3):143-9. PubMed ID: 15161996
[TBL] [Abstract][Full Text] [Related]
27. Pharmacological characterization of the nociceptin/orphanin FQ receptor non peptide antagonist Compound 24.
Fischetti C; Camarda V; Rizzi A; Pelà M; Trapella C; Guerrini R; McDonald J; Lambert DG; Salvadori S; Regoli D; Calo' G
Eur J Pharmacol; 2009 Jul; 614(1-3):50-7. PubMed ID: 19445927
[TBL] [Abstract][Full Text] [Related]
28. Characterisation of the Novel Mixed Mu-NOP Peptide Ligand Dermorphin-N/OFQ (DeNo).
Bird MF; Cerlesi MC; Brown M; Malfacini D; Vezzi V; Molinari P; Micheli L; Di Cesare Mannelli L; Ghelardini C; Guerrini R; Calò G; Lambert DG
PLoS One; 2016; 11(6):e0156897. PubMed ID: 27272042
[TBL] [Abstract][Full Text] [Related]
29. Pharmacological characterization of nociceptin/orphanin FQ receptors, a novel opioid receptor family, in the midbrain periaqueductal gray.
Chiou LC; Fan SH; Chuang KC; Liao YY; Lee SZ
Ann N Y Acad Sci; 2004 Oct; 1025():398-403. PubMed ID: 15542742
[TBL] [Abstract][Full Text] [Related]
30. Beta-arrestin 2 rather than G protein efficacy determines the anxiolytic-versus antidepressant-like effects of nociceptin/orphanin FQ receptor ligands.
Asth L; Ruzza C; Malfacini D; Medeiros I; Guerrini R; Zaveri NT; Gavioli EC; Calo' G
Neuropharmacology; 2016 Jun; 105():434-442. PubMed ID: 26867504
[TBL] [Abstract][Full Text] [Related]
31. The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence.
Witkin JM; Statnick MA; Rorick-Kehn LM; Pintar JE; Ansonoff M; Chen Y; Tucker RC; Ciccocioppo R
Pharmacol Ther; 2014 Mar; 141(3):283-99. PubMed ID: 24189487
[TBL] [Abstract][Full Text] [Related]
32. In vitro and in vivo pharmacological characterization of J-113397, a potent and selective non-peptidyl ORL1 receptor antagonist.
Ozaki S; Kawamoto H; Itoh Y; Miyaji M; Azuma T; Ichikawa D; Nambu H; Iguchi T; Iwasawa Y; Ohta H
Eur J Pharmacol; 2000 Aug; 402(1-2):45-53. PubMed ID: 10940356
[TBL] [Abstract][Full Text] [Related]
33. In vitro inhibitory effects of J-113397 on nociceptin/orphanin FQ-stimulated.
Ichikawa D; Ozaki S; Azuma T; Nambu H; Kawamoto H; Iwasawa Y; Takeshima H; Ohta H
Neuroreport; 2001 Jun; 12(8):1757-61. PubMed ID: 11409754
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the binding of [(3)H]nociceptin/orphaninFQ(1-13)NH(2), [(3)H]nociceptin/orphaninFQ(1-17)OH and [(125)I]Tyr(14)nociceptin/orphaninFQ(1-17)OH to recombinant human and native rat cerebrocortical nociceptin/orphanin FQ receptors.
Hashiba E; Lambert DG; Farkas J; Toth G; Smith G
Neurosci Lett; 2002 Aug; 328(1):5-8. PubMed ID: 12123846
[TBL] [Abstract][Full Text] [Related]
35. Characterization of the nociceptin receptor (ORL-1) agonist, Ro64-6198, in tests of anxiety across multiple species.
Varty GB; Hyde LA; Hodgson RA; Lu SX; McCool MF; Kazdoba TM; Del Vecchio RA; Guthrie DH; Pond AJ; Grzelak ME; Xu X; Korfmacher WA; Tulshian D; Parker EM; Higgins GA
Psychopharmacology (Berl); 2005 Oct; 182(1):132-43. PubMed ID: 16025321
[TBL] [Abstract][Full Text] [Related]
36. Ro 64-6198 [(1S,3aS)-8-(2,3,3a,4,5,6-Hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one] acts differently from nociceptin/orphanin FQ in rat periaqueductal gray slices.
Chiou LC; Chuang KC; Wichmann J; Adam G
J Pharmacol Exp Ther; 2004 Nov; 311(2):645-51. PubMed ID: 15254141
[TBL] [Abstract][Full Text] [Related]
37. Binding of GTPgamma[35S] is regulated by GDP and receptor activation. Studies with the nociceptin/orphanin FQ receptor.
McDonald J; Lambert DG
Br J Pharmacol; 2010 Mar; 159(6):1286-93. PubMed ID: 20148892
[TBL] [Abstract][Full Text] [Related]
38. Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists.
Khroyan TV; Polgar WE; Jiang F; Zaveri NT; Toll L
J Pharmacol Exp Ther; 2009 Dec; 331(3):946-53. PubMed ID: 19713488
[TBL] [Abstract][Full Text] [Related]
39. Novel non-peptide nociceptin/orphanin FQ receptor agonist, 1-[1-(1-Methylcyclooctyl)-4-piperidinyl]-2-[(3R)-3-piperidinyl]-1H-benzimidazole: design, synthesis, and structure-activity relationship of oral receptor occupancy in the brain for orally potent antianxiety drug.
Hayashi S; Hirao A; Imai A; Nakamura H; Murata Y; Ohashi K; Nakata E
J Med Chem; 2009 Feb; 52(3):610-25. PubMed ID: 19125610
[TBL] [Abstract][Full Text] [Related]
40. Nociceptin activation of the human ORL1 receptor expressed in Chinese hamster ovary cells: functional homology with opioid receptors.
Fawzi AB; Zhang H; Weig B; Hawes B; Graziano MP
Eur J Pharmacol; 1997 Oct; 336(2-3):233-42. PubMed ID: 9384238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
